Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

A multicenter, randomized, open-label study of dexamethasone versus romiplostim plus dexamethasone as first line treatment in patients with newly diagnosed immune thrombocytopenia: Interim results of rodex study

Blood (2025) 146 (Supplement 1): 733.

https://doi.org/10.1182/blood-2025-733

Published: 2025

Journal Articles

Sutacimig, a novel bispecific antibody for prophylactic treatment of glanzmann thrombasthenia: Analysis of a Phase 2 study

Blood (2025) 146 (Supplement 1): 842.

https://doi.org/10.1182/blood-2025-842

Published: 2025

Journal Articles

A Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sutacimig for prophylaxis in glanzmann thrombasthenia: A trial in progress

Paul Saultier, Suthesh Sivapalaratnam, Frederico Xavier, Laurent Frenzel, Andrea Artoni, Roger Schutgens, Roseline d'Oiron, Keith Gomez, Gillian Lowe, Julie Tarrant, Rajiv Pruthi, Jenny Zhou, Maissaa Janbain, Ulrike Lorch, Ashley Gosnell, Ally He, Michael Kelly, Quentin Van Thillo, Peter Verhamme

Blood (2025) 146 (Supplement 1): 8232.

https://doi.org/10.1182/blood-2025-8232

Published: 2025

Journal Articles

Velora pioneer, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of HMB-002 for prophylaxis in von Willebrand disease: A trial in progress

Priyanka Raheja, Amy Knott, Gillian Lowe, Olga Tsiamita, Ulrike Lorch, Matej Goricar, Pruthvi Nagilla, Tara O'Meara, Jigar Amin, Shivangi Mathy, Henrik Ostergaard, Benny Sorensen, Catherine Rea

Blood (2025) 146 (Supplement 1): 8230.

https://doi.org/10.1182/blood-2025-8230

Published: 2025

Journal Articles

A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia

Suthesh Sivapalaratnam, Steve Austin, Ulrike Lorch, Matej Goricar, Gillian Lowe, Ashley Gosnell, Prafull S. Gandhi, Joseph Vogel, Jigar Amin, Andrew Law, Benny Sorensen, Catherine Rea

Blood (2024) 144 (Supplement 1): 3953.1.

https://doi.org/10.1182/blood-2024-203782

Published: 2024

Journal Articles

Rapido: Results from a UK-Wide Audit of 2477 Patients Who Received a Reversal Agent for a Direct Oral Anticoagulant

Richard John Buka, Pettitt E Michala, Jasmine Makker, David J Sutton, Bryar Kadir, Andrew Doyle, Gillian Lowe, Nkemdirim Jacob, Alison Delaney, Rita Perry, Reem Ahmed, Shivir Moosai, Charlotte Hickman, Eman Hassan, HaemSTAR Collaborators, Laura Magill, Raza Alikhan, Phillip LR Nicolson

Blood (2024) 144 (Supplement 1): 2637.

https://doi.org/10.1182/blood-2024-197928

Published: 2024

Journal Articles

Retrospective, Observational, Multicenter Study Assessing the Thrombopoietin Receptor Agonist (TPO-RA) Romiplostim and Other Treatments for Patients with Newly Diagnosed or Persistent Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice in the United Kingdom (UK)

Vickie McDonald, Charlotte Bradbury, Kate Talks, Gillian Lowe, Sue Pavord, Gillian Evans, Manoharan Andiappan, Darcie Sandschafer, Vitor Jose De Sousa Barbosa, Lorraine Stephens, Nichola Cooper

Blood (2022) 140 (Supplement 1): 2678–2680.

https://doi.org/10.1182/blood-2022-157698

Published: 2022

Journal Articles

Health-Related Quality of Life Following Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in the Phase 3 Trial GENEr8-1

Blood (2021) 138 (Supplement 1): 4916.

https://doi.org/10.1182/blood-2021-146021

Published: 2021

Journal Articles

Real-world experience with caplacizumab in the management of acute TTP

Blood (2021) 137 (13): 1731–1740.

https://doi.org/10.1182/blood.2020007599

Published: 2021

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A multicenter, randomized, open-label study of dexamethasone versus romiplostim plus dexamethasone as first line treatment in patients with newly diagnosed immune thrombocytopenia: Interim results of rodex study

Sutacimig, a novel bispecific antibody for prophylactic treatment of glanzmann thrombasthenia: Analysis of a Phase 2 study

A Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sutacimig for prophylaxis in glanzmann thrombasthenia: A trial in progress

Velora pioneer, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of HMB-002 for prophylaxis in von Willebrand disease: A trial in progress

A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia

Rapido: Results from a UK-Wide Audit of 2477 Patients Who Received a Reversal Agent for a Direct Oral Anticoagulant

Retrospective, Observational, Multicenter Study Assessing the Thrombopoietin Receptor Agonist (TPO-RA) Romiplostim and Other Treatments for Patients with Newly Diagnosed or Persistent Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice in the United Kingdom (UK)

Health-Related Quality of Life Following Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in the Phase 3 Trial GENEr8-1

Real-world experience with caplacizumab in the management of acute TTP

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only